Hepatitis C virus subtype distribution and resistance-associated substitutions in high-risk population groups in Guangdong Province, China

被引:1
|
作者
Xie, Shilan [1 ]
Yan, Jin [2 ]
Fu, Xiaobing [1 ]
Yu, Guolong [2 ]
Yan, Xinge [2 ]
Yang, Fang [1 ]
Li, Bosheng [2 ]
机构
[1] Inst HIV AIDS Prevent, Guangdong Prov Ctr Dis Control & Prevent, Guangzhou 511430, Guangdong, Peoples R China
[2] Guangdong Prov Ctr Dis Control & Prevent, Inst Pathogen Microorg, RM 2528,160 Qunxian Rd, Guangzhou 511430, Guangdong, Peoples R China
关键词
Hepatitis C virus; Subtype; NS5A; Resistance-associated substitution; Guangdong; GENOTYPE; 6; ANTIVIRAL DRUGS; HCV INFECTION; PREVALENCE; TRANSMISSION; PATTERNS; NS5A; NS3;
D O I
10.1016/j.meegid.2024.105653
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objective: In Guangdong Province, hepatitis C virus (HCV) had been found to confer resistance to direct-acting antivirals (DAAs). There were few studies of HCV subtypes and resistance-associated substitutions (RASs) of HCV in different high-risk populations. In this study, we aimed to determine the subtype distribution and the RASs in high-risk population groups, including drug users (DU), men who have sex with men (MSM), female sex workers (FSW), and male patients with sexually transmitted diseases (STD) in Guangdong Province (a highly developed province with a large population). Methods: Using a city-based sampling strategy,1356 samples were obtained from different population groups. Phylogenetic analyses determined subtypes based on Core, NS5B, or NS5A sequences. HCV subtype distribution and RASs in various risk groups and regions were analyzed. Results: Ten subtypes, of which 6 h and 6 k were novel in Guangdong, were identified. The primary subtype among all risk groups was 6a. RASs in 1b and 3a were different from those observed in other studies. Subtype 3b in western Guangdong was higher than the other three regions. No RASs were found in 6a or any other genotype 6. Conclusions: The HCV subtypes are expanding in high-risk populations in Guangdong. Drug use by other risk groups and commercial sex by DU may bridge the dissemination of 6a from DU to other populations. The RAS profiles of 1b and 3a differed from those reported in studies conducted in southwestern China. Further research is required to determine the reason for this discrepancy. Moreover, the combination of RASs was high in subtype 3b. To guide HCV treatment of subtype 3b, pretreatment subtyping of HCV genotype 3 should be considered in western cities in the near future.
引用
收藏
页数:8
相关论文
共 50 条
  • [1] Hepatitis C Virus Resistance-Associated Substitutions in Mexico
    Jose-Abrego, Alexis
    Laguna-Meraz, Saul
    Roman, Sonia
    Mariscal-Martinez, Irene M.
    Panduro, Arturo
    VIRUSES-BASEL, 2025, 17 (02):
  • [2] Hepatitis C virus drug resistance-associated substitutions: State of the art summary
    Lontok, Erik
    Harrington, Patrick
    Howe, Anita
    Kieffer, Tara
    Lennerstrand, Johan
    Lenz, Oliver
    McPhee, Fiona
    Mo, Hongmei
    Parkin, Neil
    Pilot-Matias, Tami
    Miller, Veronica
    HEPATOLOGY, 2015, 62 (05) : 1623 - 1632
  • [3] Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment
    Auda A. Eltahla
    Preston Leung
    Mehdi R. Pirozyan
    Chaturaka Rodrigo
    Jason Grebely
    Tanya Applegate
    Lisa Maher
    Fabio Luciani
    Andrew R. Lloyd
    Rowena A. Bull
    Scientific Reports, 7
  • [4] Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions
    Ezequiel Ridruejo
    Matías Javier Pereson
    Diego M Flichman
    Federico Alejandro Di Lello
    World Journal of Hepatology, 2021, (09) : 1069 - 1078
  • [5] Resistance-associated substitutions in patients with chronic hepatitis C virus genotype 4 infection
    Dietz, Julia
    Kalinina, Olga, V
    Vermehren, Johannes
    Peiffer, Kai-Henrik
    Matschenz, Katrin
    Buggisch, Peter
    Niederau, Claus
    Schattenberg, Jorn M.
    Muellhaupt, Beat
    Yerly, Sabine
    Ringelhan, Marc
    Schmid, Roland M.
    Antoni, Christoph
    Mueller, Tobias
    zur Wiesch, Julian Schulze
    Piecha, Felix
    Moradpour, Darius
    Deterding, Katja
    Wedemeyer, Heiner
    Moreno, Christophe
    Berg, Thomas
    Berg, Christoph P.
    Zeuzem, Stefan
    Welsch, Christoph
    Sarrazin, Christoph
    JOURNAL OF VIRAL HEPATITIS, 2020, 27 (10) : 974 - 986
  • [6] Hepatitis C virus treatment failure: Clinical utility for testing resistance-associated substitutions
    Ridruejo, Ezequiel
    Pereson, Matias Javier
    Flichman, Diego M.
    Di Lello, Federico Alejandro
    WORLD JOURNAL OF HEPATOLOGY, 2021, 13 (09) : 1069 - 1078
  • [7] Prevalence of resistance-associated substitutions and phylogenetic analysis of hepatitis C virus infection in Russia
    Isakov, Vasily
    Hedskog, Charlotte
    Wertheim, Joel O.
    Hostager, Reilly E.
    Parhy, Bandita
    Schneider, Adriano De Bernardi
    Suri, Vithika
    Mo, Hongmei
    Geivandova, Natalia
    Morozov, Vyacheslav
    Bessonova, Elena
    Gankina, Natalya
    Zhdanov, Konstantin
    Abdurakhmanov, Dzhamal
    Svarovskaia, Evguenia
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2021, 113 : 36 - 42
  • [8] Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment
    Eltahla, Auda A.
    Leung, Preston
    Pirozyan, Mehdi R.
    Rodrigo, Chaturaka
    Grebely, Jason
    Applegate, Tanya
    Maher, Lisa
    Luciani, Fabio
    Lloyd, Andrew R.
    Bull, Rowena A.
    SCIENTIFIC REPORTS, 2017, 7
  • [9] Molecular characterization of hepatitis C virus for subtype determination and resistance-associated substitutions detection among Chinese voluntary blood donors
    Jiang, Xinyi
    Lv, Xiaoting
    Chang, Le
    Yan, Ying
    Ji, Huimin
    Sun, Huizhen
    Guo, Fei
    Rodgers, Mary A.
    Yin, Peng
    Wang, Lunan
    ANTIVIRAL RESEARCH, 2020, 181
  • [10] Prevalence of resistance-associated substitutions (RAS) in hepatitis C virus in the Former Soviet Union countries
    Mustafa, Aidana
    Davlidova, Salima
    Abidi, Syed Hani
    Begimbetova, Dinara
    Heimer, Robert
    Vermund, Sten H.
    Ali, Syed
    BMJ OPEN GASTROENTEROLOGY, 2025, 12 (01):